Table 5.
Classification by Turin proposal | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# | Age | Sex | Primary tumor | Lymph node metastasis | Tumor size (cm) | Margin status | Total number of lymph nodes with metastasis | Size of the largest lymph node (cm) | Mode of death | Time to death (years) | Site of DM | ATA 2015 risk stratification | Response to treatment |
1 | 58 | M | PTC, microcarcinomaa | Follicular variant PTC | 0.4 | Negative | 2 | 3.2 | Distant | 8.4 | Lung, bone, retroperitoneum | High risk | Biochemical incomplete response |
2 | 82 | F | Tall-cell variant PTC | Tall-cell variant PTC | 4.1 | Positive | 4 | 1.2 | Distant | 1.4 | Lung | Intermediate risk | Structural incomplete response |
3 | 70 | F | Tall-cell variant PTC | Tall-cell variant PTC | 1.8 | Positive | 8 | 0.6 | Distant | 11.3 | Lung | Intermediate risk | Excellent response |
4 | 78 | F | Columnar variant PTC | NA | 2.5 | Negative | NA | NA | Distant | 3.1 | Lung | Intermediate risk | Structural incomplete response |
5 | 72 | F | Classical variant PTC | Classical variant PTC | 2 | Negative | 3 | 0.6 | Unknown | 11.9 | Lung | Low risk | Excellent response |
This is the patient shown in Figure 2.
ATA, American Thyroid Association.